ACUTE-PHASE EFFICACY IN A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZS-9 FOR HYPERKALAEMIA

被引：0
|
作者：
El-Shahawy, Mohamed A. [1 ]
Rasmussen, Henrik S. [2 ]
Lavin, Philip T. [3 ]
Yang, Alex [4 ]
Packham, David K. [5 ]
机构：
[1] Acad Med Res Inst, Los Angeles, CA USA
[2] ZS Pharma Inc, Coppell, TX USA
[3] Boston Biostat Res Fdn, Framingham, MA USA
[4] Xelay Acumen Inc, Belmont, CA USA
[5] Melbourne Renal Res Grp, Melbourne, Vic, Australia
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2014年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP320
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [1] EXTENDED EFFICACY OF ZS-9 ONCE-DAILY IN A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH HYPERKALAEMIA
    Roger, Simon D.
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    Qunibi, Wajeh Y.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 182 - 182
  • [2] SAFETY AND TOLERABILITY OF ZS-9 IN A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH HYPERKALAEMIA
    Packham, David K.
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    Qunibi, Wajeh Y.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 184 - 184
  • [3] EFFICACY OF ZS-9 IN PATIENTS RECEIVING RAAS THERAPY: A SUBGROUP ANALYSIS OF A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Roger, Simon D.
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    El-Shahawy, Mohamed A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 180 - 180
  • [4] PHASE 3, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZS-9: SUBGROUP ANALYSIS STRATIFIED BY BASELINE SERUM POTASSIUM LEVELS
    Singh, Bhupinder
    Rasmussen, Henrik S.
    Lavin, Phillip T.
    Yang, Alex
    Roger, Simon D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 178 - 179
  • [5] ACUTE-PHASE EFFICACY OF ZS-9 IN PATIENTS WITH BASELINE SERUM POTASSIUM LEVELS ABOVE 5.5 MECVL: ANALYSIS FROM A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL
    El-Shahawy, Mohamed
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    Packham, David K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A878 - A878
  • [6] Maintenance of normal serum K+ with ZS-9 once daily in patients with CHF: subgroup analysis of a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of patients with hyperkalaemia
    El-Shahawy, M. A.
    Singh, B.
    Rasmussen, H. S.
    Lavin, P. T.
    Yang, A.
    Qunibi, W.
    EUROPEAN HEART JOURNAL, 2014, 35 : 722 - 722
  • [7] Achievement of Normokalemia with ZS-9 Across Subgroups in a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Hyperkalemia
    Singh, Bhupinder
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    El-Shahawy, Mohamed A.
    HYPERTENSION, 2014, 64
  • [8] INDIVIDUALIZING ZS-9 DOSING FOR SERUM POTASSIUM REDUCTION IN HYPERKALEMIC PATIENTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Lavin, Philip T.
    Yang, Alex
    Singh, Bhupinder
    Rasmussen, Jacob
    Stavros, Fiona
    Winger, Roland
    Kovalsky, Matthew P.
    Sorrells, Brent
    Rasmussen, Henrik S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) : A119 - A119
  • [9] PLACEBO EFFECT IN CLINICAL STUDIES IN HYPERKALEMIA: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9)
    Yang, Alex
    Singh, Bhupinder
    Lavin, Philip T.
    Chang, Alan
    Rasmussen, Henrik S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A91 - A91
  • [10] NORMALIZATION OF SERUM BICARBONATE WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY
    de Francisco, Angel
    Rasmussen, Henrik
    Lavin, Philip
    Singh, Bhupinder
    Yang, Alex
    Mann, Johannes
    Jadoul, Michel
    Spinowitz, Bruce
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
12345